ARMP - AMEX
Armata Pharmaceuticals, Inc.
$7.93
+0.13%Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
At a Glance
Live SnapshotArmata Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Armata Pharmaceuticals, Inc. Cash Flow Statement
ARMP • AMEX
| Armata Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 | Dec 2004 | Dec 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-173.8M | -18.9M | -69M | -36.9M | -23.2M | -22.2M | -19.5M | -12.1M | -12.8M | -18.8M | -516K | 23.1M | -58.4M | -4.3M | -20.7M | -16.1M | -34M | -19.2M | -14.3M | -14.8M | |
1.5M | 1.3M | 972K | 892K | 1.2M | 1.1M | 1.4M | 389K | 374K | 369K | 330K | 158K | 82K | 91K | 516K | 602K | 720K | 1.3M | 1.3M | 2.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -454K | -328K | -1.3M | -556K | -73K | 0.0 | 43.2M | -1K | 7.8M | -650K | 0.0 | 0.0 | 0.0 | 0.0 | |
2.6M | 2.9M | 938K | 3.1M | 2.9M | 3.5M | 4.3M | 478K | 700K | 2M | 483K | 1.9M | 1.4M | 9K | 718K | 966K | 0.0 | 0.0 | 0.0 | 0.0 | |
145.3M | -20.8M | 29.4M | 0.0 | -1.2M | 196K | 918K | 1.8M | 4.3M | 5.8M | -9.8M | -37.2M | 5.2M | 31K | -87K | 966K | 22.1M | 124K | -994K | 822K | |
-1.4M | -2.1M | -9.6M | 439K | -3.2M | -874K | -2.2M | 345K | -457K | 670K | -158K | -556K | 1.1M | -151K | 1.4M | 361K | -508K | 1.4M | -1.6M | 361K | |
-25.8M | -37.6M | -47.4M | -32.5M | -23.6M | -18.3M | -15.6M | -9.4M | -9.2M | -10.6M | -9.8M | -12.6M | -7.4M | -4.3M | -10.3M | -13.9M | -11.6M | -16.4M | -15.5M | -11.2M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-542K | -1.9M | -8.1M | -2.2M | -1.3M | -824K | -131K | -44K | -58K | -279K | -210K | -1.2M | -102K | -53K | -738K | -554K | -81K | -669K | -408K | -316K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3M) | (65K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16K | 16K | 49K | 57K | 0.0 | 0.0 | |
0.0 | 0.0 | 10K | 0.0 | 0.0 | 0.0 | 0.0 | 9.7M | -1.9M | 0.0 | 0.0 | 0.0 | 204K | 3.2M | 60K | 24K | 0.0 | 0.0 | 0.0 | 0.0 | |
-542K | -1.9M | -8.1M | -2.2M | -1.3M | -824K | (2.9M) | -44K | -58K | -279K | -210K | -1.2M | -102K | (3.1M) | -662K | -514K | -32K | -612K | -408K | -316K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
658K | 130K | 5K | 44.5M | 26.3M | 22.9M | 10M | 12.2M | 9.4M | 7.6M | 12.4M | 0.0 | 18M | 0.0 | 0.0 | 26M | 4.9M | 28K | 29.8M | 21M | |
25M | 34.9M | 54M | 0.0 | 0.0 | 717K | 0.0 | 0.0 | -815K | -100K | 0.0 | 0.0 | 2M | 950K | -259K | -1.4M | -1.2M | -3M | -820K | -1M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -80K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-46K | -61K | -43K | -500K | -801K | -400K | -1M | 203K | 133K | 13K | 396K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
25.6M | 35M | 54M | 44M | 25.5M | 23.2M | 9M | 12.5M | 8.7M | 7.2M | 12.8M | 0.0 | 27M | 950K | -259K | 24.6M | 3.8M | -3M | 29M | 20M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | -4.8M | 0.0 | 0.0 | 0.0 | 0.0 | -1K | 0.0 | 0.0 | 0.0 | 41K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-693K | -4.5M | -1.6M | 4.6M | 639K | 4.1M | -3.7M | 3M | -579K | -3.7M | 2.8M | -13.8M | 19.5M | -234K | -11.2M | 10.2M | -7.9M | -20M | 13M | 8.5M | |
14.8M | 19.2M | 20.8M | 10.3M | 10.8M | 6.7M | 10.5M | 5.1M | 5.7M | 9.4M | 6.6M | 20.4M | 862K | 1.1M | 16.4M | 6.2M | 14.1M | 34.1M | 21.1M | 12.6M | |
14.1M | 14.8M | 19.2M | 14.9M | 11.5M | 10.8M | 6.7M | 8.2M | 5.1M | 5.7M | 9.4M | 6.6M | 20.4M | 862K | 5.2M | 16.4M | 6.2M | 14.1M | 34.1M | 21.1M | |
-26.3M | -39.4M | -55.6M | -34.7M | -24.9M | -19.1M | -15.7M | -9.4M | -9.3M | -10.9M | -10M | -13.8M | -7.6M | -4.3M | -11M | -14.4M | -11.7M | -17.1M | -15.9M | -11.5M |
SEC Filings
ARMP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 |
Related Guides
Continue your ARMP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.